Mergers and Acquisitions

Who's Bought Who in the Late Summer Sales

Who's Bought Who in the Late Summer Sales

By Dan Stanton

Amgen spent $10.4bn (€7.8bn) this week on Onyx Pharmaceuticals, but AstraZeneca and Johnson & Johnson have also opened up their wallets this week – welcome to in-Pharmatechnologist.com’s merger & acquisition round-up.

Amgen Acquires Onyx for $10.4bn

Amgen Acquires Onyx for $10.4bn

Amgen has spent $10.4bn (€7.8bn) in acquiring Onyx Pharmaceuticals saying its oncology products and pipeline will be strengthened by Amgen’s manufacturing capabilities.

AB Technology Buys Angel's Edinburgh Assets

AB Technology Buys Angel's Edinburgh Assets

By Dan Stanton

As the dissolution of Angel continues, its core manufacturing facility has been bought by AB Technology ensuring long term operations and rescuing 23 jobs.

Symrise inceases Probi stake; formalises R&D partnership

Symrise-Probi partnership to deliver probiotic goods in 2014-15

By Shane Starling

German fragrance and flavours house Symrise has just last night inked a deal with Swedish probiotics firm Probi to develop a stand-alone R&D project with oral probiotic supplements the most likely product out of the pipeline in 2014-2015.